Dyne Therapeutics, Inc. $DYN Shares Sold by Braidwell LP

Key Points

• Braidwell LP cut its Dyne Therapeutics stake by 45.2% in the second quarter, selling 760,400 shares and retaining 921,598 shares worth approximately $20.5 million. Institutional investors collectively own 96.68% of the company.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $34.42. Recent targets range from $24 to $50, although one firm downgraded the stock to “Strong Sell.”
• Dyne shares opened at $25.14, near their 52-week high, while the company reported a quarterly loss of $1.08 per share versus the expected $0.75 loss. Insider selling has been substantial, including a director’s $54 million sale, with insiders selling about $99.4 million of stock over the past 90 days.

Braidwell LP lessened its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 45.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 921,598 shares of the company's stock after selling 760,400 shares during the period. Braidwell LP owned approximately 0.49% of Dyne Therapeutics worth $20,469,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. AQR Capital Management LLC purchased a new position in shares of Dyne Therapeutics in the first quarter worth $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Dyne Therapeutics by 5.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company's stock valued at $597,000 after buying an additional 2,886 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Dyne Therapeutics by 58.2% during the first quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company's stock valued at $10,407,000 after buying an additional 366,183 shares during the last quarter. Caxton Associates LLP acquired a new position in shares of Dyne Therapeutics in the 1st quarter valued at $157,000. Finally, Creative Planning increased its position in shares of Dyne Therapeutics by 23.8% in the 2nd quarter. Creative Planning now owns 14,541 shares of the company's stock valued at $138,000 after acquiring an additional 2,797 shares during the period. Institutional investors and hedge funds own 96.68% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. HC Wainwright restated a "buy" rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research note on Monday, August 17th. Morgan Stanley cut their price objective on Dyne Therapeutics from $47.00 to $45.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. Wall Street Zen cut Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 1st. Sanford C. Bernstein lifted their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a "market perform" rating in a report on Wednesday, May 13th. Finally, Royal Bank Of Canada upped their target price on Dyne Therapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a research report on Thursday, July 30th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $34.42.

Dyne Therapeutics Trading Up 0.2%

NASDAQ DYN opened at $25.14 on Thursday. The company has a market capitalization of $4.69 billion, a PE ratio of -7.55 and a beta of 1.08. The company has a fifty day moving average of $24.65 and a 200 day moving average of $20.26. Dyne Therapeutics, Inc. has a 1 year low of $11.92 and a 1 year high of $27.31. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). Research analysts forecast that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current year.

Insider Activity

In other Dyne Therapeutics news, CFO Erick Lucera sold 2,362 shares of the business's stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.37, for a total value of $48,113.94. Following the completion of the transaction, the chief financial officer directly owned 121,563 shares of the company's stock, valued at approximately $2,476,238.31. The trade was a 1.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jason P. Rhodes sold 2,160,516 shares of the company's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the sale, the director owned 428,946 shares in the company, valued at approximately $10,723,650. This represents a 83.43% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 4,139,196 shares of company stock worth $99,449,852. 9.46% of the stock is owned by corporate insiders.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source